Metabolic Disorders of Vitamin B6 in Chronic Kidney Disease Patients

Abstract

Background. Vitamin B6 (VB6) is a water soluble vitamin
which is important for the normal function of multiple
organ systems. It is metabolized to the active molecule
pyridoxal-5-phosphate (PLP).
Purpose of the study was to investigate the metabolic disorders
of VB6 in patients (pts) with various chronic
kidney diseases (CKD).
Methods. Erythrocyte (Er) VB6 was investigated in 15
pts suffering from chronic glomerulonephritis and nephrotic
syndrome (CG NS), GFR stage 1; urinary excretion
(UE) of VB6 was investigated in 15 healthy subjects
during maximal water diuresis, in 12 pts with
CKD, GFR stage 3 - 4, during the diet with restriction
(2g/day) or high intake (15g/day) of NaCl and in other
group of 15 CKD pts, GFR stage 3-4, after i.v. administration
of 20 mg furosemide. The effect of 50 mg
pyridoxine (P)/day on several parameters of cellular
immunity in haemodialysis (HD) pts was investigated.
In addition Er VB6 was investigated in 16 HD pts during
erythropoietin (EPO) treatment. Vitamin B6 in plasma
and urine was determined by radioenzymatic assay,
and Er VB6 was determined by means of an indirect method
and it was expressed as the effect of PLP in per
cents. Plasma oxalic acid was determined by spectrophotometric
method using oxalate oxidase which is free
from vitamin C interference.


lebih lengkap download disni gratis